All In Biotech

Drug Trial Radar · NCT00386061

Rimonabant in Obesity Over a 2-Year Duration (RIO-Europe)

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dose, Multicenter Study of Weight-Reducing Effect and Safety of SR141716 in Obese Patients With or Without Comorbidities (RIO-Europe)

Last checked: Nov 20, 2026Latest source record: Apr 20, 2009 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 1,507 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,507

Actual

Start

Oct 2001

Primary completion

Jun 2004

Study completion Jun 2004

Sponsor

Lead sponsor
SanofiSanofi (SNY)
Sponsor type
Industry
First posted
Oct 11, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective was to assess the effect of SR141716 on weight loss and weight maintenance over a period of one year when prescribed with a hypocaloric diet in obese patients with or without comorbidities. The main secondary objectives were to assess the effect of SR141716 on lipid parameters (HDL-C, TG), glucose tolerance status, the rate of patients with metabolic syndrome, waist circumference, glycemic parameters.

Conditions

  • Obesity

Interventions

  • rimonabant (SR141716)Drug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. change in body weight from baseline to 1 year.

Locations

7 sites in 7 countries. Site status is shown where the registry gives one.

  • Sanofi-Aventis

    Bridgewater, New Jersey

  • Sanofi-Aventis

    Brussels, Belgium

  • Sanofi-Aventis

    Helsinki, Finland

  • Sanofi-Aventis

    Paris, France

  • Sanofi-Aventis

    Berlin, Germany

  • Sanofi-Aventis

    Gouda, Netherlands

  • Sanofi-Aventis

    Bromma, Sweden

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.